Know-how, science and technology in ophthalmology

OFTALABS combines the skills, passion, and interests of practising physicians and researchers to come up with solutions that could be used in the protection of the eye and the treatment of eye diseases.

ABOUT

OFTALABS is a Polish Ophthalmological Research and Development company. OFTALABS was created to come up with innovative solutions that would develop the Polish ophthalmology and lead to the protection of the eye and to the treatment of eye diseases. We combine the know-how, passion, and interests of practising physicians and researchers from different fields of science. We conduct our research projects and we help with the organisation, finances, legal aspects, and business plans and commercialisation of other scientific projects.

CEO – Maciej Osęka, MD, PhD

1986-1992

Maciej Osęka graduated from the Klementyna Hoffmanowa high school in Warsaw (1986) and from the Faculty of Medicine, Warsaw Medical University (1992). As a student he was part of the scientific association of the Department of General and Applied Physiology, where he started his academic work.

1992-1997

Between 1992-1997 he worked as assistant resident at the Department of Clinical and Applied Physiology, Warsaw Medical University.

1998

In 1998 he received his PhD with distinction from the Warsaw Medical University for his thesis: “The role of endothelial cells of blood vessels in the cerebral circulation in normotensive rats and in rats genetically predisposed to arterial hypertension”.

1996-1998

In 1998 he graduated from the International Management Centre, Warsaw University, with a MA in Marketing and Management. He has been working for pharmaceutical companies since 1998.

1999-2009

Between 1999-2009 he was the director of Dr. Mann Pharma Poland and from mid-2005 he was also the Managing Director and the Pharmaceutical Director at Bausch&Lomb Poland. During that time he introduced many new ophthalmology products, most of which became leading products on their markets, and Dr Mann Pharma/Bausch&Lomb Poland became the third biggest ophthalmology company in Poland (comparing to 11th position in 1999), generating a turnover of around 50 million PLN a year.

2010-2018

He was the CEO and co-owner of Ofta Sp. z o.o. between 2010-2018. He collaborated with numerous scientific centres on the preparation and implementation of innovative ophthalmology products including Demoxoft, Retixoft, HexaClean, Dexoftyal, Vitroft, Cataroft, Hexoftyal, and Maculoft. In 2017 Ofta generated a turnover of around 25 million PLN.

Maciej Osęka, MD, PhD, is the member of numerous scientific associations (including the Association for Research for Vision and Ophthalmology (ARVO) and the European Association for Vision and Eye Research (EVER)) and the author and co-author of several patents and dozens of research papers presented at national and international conferences and published in scientific journals (please check Researchgate for more research information).

COLLABORATIVE RESEARCH

OFTALABS collaborates with clinical centres and private ophthalmology and academic science centres specialised among others in virology, microbiology, molecular biology, general biology, physiology and pathophysiology, parasitology, dermatology, and optical engineering.

OFTALABS conducts its individual innovative research and supports Polish scientists and clinicists financially, organisationally, and legally in their research; it also helps them to increase their qualifications and to collaborate with other research and clinical centres and national and international companies in order to implement the results of studies and experiments.

INDIVIDUAL RESEARCH

EXUDING AGE-RELATED MACULAR DEGENERATION (AMD) AND DIABETIC MACULOPHATY
The impact of vascular endothelial growth factor inhibitors (VEGF-inhibitors) and its potential use in the treatment of exudative Age-related Macular Degeneration (AMD) and diabetic maculophaty.

2 patents, 1 pending

DIABETIC RETINOPATHY
The use of antioxidants and neuroprotective agents in diabetic retinopathy prevention and treatment.

ANTIBIOTIC RESISTANCE IN OPHTALMOLOGY
Preparation of solutions susceptible of decreasing the increasing antibiotic resistance in ophthalmology.

FAST DIAGNOSTICS OF SELECTED EYE DISEASES
Research of fast diagnostic methods of eye diseases and of systemic disease complications, such as diabetes.

CONTACT

Oftalabs Sp. z o.o.

Wałbrzyski Inkubator Przedsiębiorczości
ul. Młynarska 29
58-300 Wałbrzych

Tel.: +48 605 47 47 81
E-mail: office@oftalabs.pl

CONTACT FORM

Thank you for your interest in OFTALABS.
Please fill in the form and we will get back in touch!